Flurazepam Hydrochloride Capsule

What This Flurazepam Shortage Record Means

The FDA Drug Shortages database lists this record for Flurazepam Hydrochloride Capsule from Rising Pharma Holdings, Inc. with a current status of Active Shortage. The affected dosage form is Capsule, presented as Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01). Shortages are tracked at the manufacturer and presentation level — other manufacturers or formulations of the same generic may remain available, which is why pharmacists often can source a working substitute even when one record is flagged.

This shortage was first reported on Aug 3, 2022 and was last updated Jan 14, 2026. The FDA cites the following reason: Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility. There are 5 other current records in this database covering the same generic, which gives a fuller picture of how disruption is playing out across manufacturers and dosage forms.

A shortage listing is a supply-side signal, not a patient-level instruction. Access can vary dramatically by pharmacy, region, hospital system, and insurance formulary — local pharmacists have real-time visibility that a national database cannot provide. Therapeutic substitutes often exist in the same class, but switching decisions belong with your prescriber, who weighs efficacy, dosing conversion, interaction profile, and personal history. This page summarizes public FDA data for educational reference only and is not medical advice. If your medication is affected, contact your pharmacist and prescriber to plan an appropriate response.